Zura Bio Ltd (ZURA) News

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa...

Form 8-K - Current report

Zura Bio to Participate in Two Upcoming Investor Conferences in November

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for...

Form 8-K - Current report

Form 8-K - Current report

Form S-3/A - Registration statement under Securities Act of 1933: [Amend]

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]